Connecticut doctor develops personalized cancer vaccines, shows promise

A new trial led by Dr. David Braun at Yale School of Medicine tested personalized cancer vaccines on nine patients with advanced kidney cancer. The vaccines, made from the patients' own cancer cells, showed promising results, with patients remaining cancer-free for about three years. The trial is part of a larger study enrolling 270 participants, which will use a computer to select patients for a blind study. This new approach aims to enhance the immune system's ability to target cancer cells effectively. While initial results are encouraging, experts emphasize the need for further validation. The research, supported by the National Institutes of Health, was published in Nature on February 5.